Literature DB >> 6393864

Activities of respository preparations of cycloguanil pamoate and 4,4'-diacetyldiaminodiphenylsulfone, alone and in combination, against infections with Plasmodium cynomolgi in rhesus monkeys.

L H Schmidt, R N Rossan.   

Abstract

The studies summarized in this report were concerned with the capacities of repository preparations of cycloguanil pamoate (CGT-P) to protect rhesus monkeys against infections with drug-susceptible and pyrimethamine-resistant strains of Plasmodium cynomolgi. Administered intramuscularly as a suspension in an oleaginous vehicle, CGT-P (i) provided long-term protection against single and repetitive challenges of rhesus monkeys with sporozoites of the drug-susceptible B and Ro strains, (ii) effected prompt clearance of parasitemia in established infections, and (iii) delayed relapse. Protection was equated to absence of parasites on thick blood films, negative results when blood was transferred to susceptible recipients, and inability to activate infection by splenectomy. Eventual loss of protection was not related to emergence of parasites resistant to cycloguanil (CGT). Although protection varied from monkey to monkey, its mean duration was related directly to size of CGT-P dose and size of particles in the suspension. Urinary excretion studies indicated that protection persisted as long as the daily output of CGT did not fall below that attained with the parenterally administered hydrochloride salt at a dose equivalent to 0.015 mg of CGT per kg. Studies on infections with the resistant Ro/PM strain showed that the activity of CGT-P was compromised severely by resistance to pyrimethamine. Attempts to minimize this liability by concomitant administration of 4,4'-diacetyldiaminodiphenylsulfone met with limited success. These results suggest that even the best of the repository preparations of CGT-P, with or without 4,4'-diacetyldiaminodiphenylsulfone, would be useful only in areas where Plasmodium falciparum and Plasmodium vivax are fully susceptible to chlorguanide and pyrimethamine.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6393864      PMCID: PMC179984          DOI: 10.1128/AAC.26.5.611

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  46 in total

1.  THE ANTIMALARIAL ACTIVITY OF CI-501 (CAMOLAR) AGAINST FALCIPARUM MALARIA.

Authors:  P G CONTACOS; G R COATNEY; J S LUNN; J W KILPATRICK
Journal:  Am J Trop Med Hyg       Date:  1964-05       Impact factor: 2.345

2.  A metabolite of paludrine with high antimalarial activity.

Authors:  H C CARRINGTON; A F CROWTHER; D G DAVEY; A A LEVI; F L ROSE
Journal:  Nature       Date:  1951-12-22       Impact factor: 49.962

3.  Studies in human malaria. XXX. A summary of 204 sporozoite-induced infections with the Chesson strain of Plasmodium vivax.

Authors:  G R COATNEY; W C COOPER; M D YOUNG
Journal:  J Natl Malar Soc       Date:  1950-12

Review 4.  Progress in malaria chemotherapy. 1. Repository antimalarial drugs.

Authors:  E F Elslager
Journal:  Prog Drug Res       Date:  1969

5.  A study among African school-children of the repository antimalarial properties of cycloguanil pamoate, 4,4+-diacetyldiaminodiphenylsulfone, and a combination of the two drugs.

Authors:  A B Laing; G Pringle; F C Lane
Journal:  Am J Trop Med Hyg       Date:  1966-11       Impact factor: 2.345

6.  An evaluation of CI-564 against blood-induced chlorguanide-sensitive and chlorguanide-resistant strains of vivax malaria.

Authors:  W Chin; G R Coatney; H K King
Journal:  Am J Trop Med Hyg       Date:  1967-01       Impact factor: 2.345

7.  Resistance to cycloguanil pamoate (CI-501) by falciparum malaria in West Pakistan.

Authors:  P G Contacos; G R Coatney; J S Lunn; W Chin
Journal:  Am J Trop Med Hyg       Date:  1965-11       Impact factor: 2.345

8.  [Study on the antimalarial activity of dihydrotriazine pamoate C. I. Camolar].

Authors:  M Payet; P Pène; R Michel; M Sankalé; J C Bernou; I Gueye
Journal:  Bull Soc Pathol Exot Filiales       Date:  1968

9.  Plasmodium falciparum and Plasmodium vivax infections in the owl monkey (Aotus trivirgatus). III. Methods employed in the search for new blood schizonticidal drugs.

Authors:  L H Schmidt
Journal:  Am J Trop Med Hyg       Date:  1978-07       Impact factor: 2.345

10.  STUDIES ON A STRAIN OF CHLOROQUINE-RESISTANT PLASMODIUM FALCIPARUM FROM VIET-NAM.

Authors:  R D POWELL; G J BREWER; R L DEGOWIN; A S ALVING
Journal:  Bull World Health Organ       Date:  1964       Impact factor: 9.408

View more
  1 in total

Review 1.  Injectable anti-malarials revisited: discovery and development of new agents to protect against malaria.

Authors:  Fiona Macintyre; Hanu Ramachandruni; Jeremy N Burrows; René Holm; Anna Thomas; Jörg J Möhrle; Stephan Duparc; Rob Hooft van Huijsduijnen; Brian Greenwood; Winston E Gutteridge; Timothy N C Wells; Wiweka Kaszubska
Journal:  Malar J       Date:  2018-11-01       Impact factor: 2.979

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.